Skeletal  ||| S:0 E:9 ||| JJ
effects  ||| S:9 E:17 ||| NNS
of  ||| S:17 E:20 ||| IN
oral  ||| S:20 E:25 ||| JJ
anticoagulants  ||| S:25 E:40 ||| JJ
Vitamin  ||| S:40 E:48 ||| NNP
K  ||| S:48 E:50 ||| NNP
antagonists  ||| S:50 E:62 ||| NNS
( ||| S:62 E:63 ||| -LRB-
VKA ||| S:63 E:66 ||| NNP
)  ||| S:66 E:68 ||| -RRB-
are  ||| S:68 E:72 ||| VBP
often  ||| S:72 E:78 ||| RB
used  ||| S:78 E:83 ||| VBN
as  ||| S:83 E:86 ||| IN
oral  ||| S:86 E:91 ||| JJ
anticoagulants  ||| S:91 E:106 ||| NNS
( ||| S:106 E:107 ||| -LRB-
OA ||| S:107 E:109 ||| NNP
)  ||| S:109 E:111 ||| -RRB-
in  ||| S:111 E:114 ||| IN
order  ||| S:114 E:120 ||| NN
to  ||| S:120 E:123 ||| TO
prevent  ||| S:123 E:131 ||| VB
thromboembolic  ||| S:131 E:146 ||| JJ
diseases ||| S:146 E:154 ||| NNS
.  ||| S:154 E:156 ||| .
In  ||| S:156 E:159 ||| IN
bone ||| S:159 E:163 ||| NN
,  ||| S:163 E:165 ||| ,
vitamin  ||| S:165 E:173 ||| VBG
K  ||| S:173 E:175 ||| NNP
reduces  ||| S:175 E:183 ||| VBZ
bone  ||| S:183 E:188 ||| JJ
resorption  ||| S:188 E:199 ||| NN
and  ||| S:199 E:203 ||| CC
functions  ||| S:203 E:213 ||| NNS
as  ||| S:213 E:216 ||| IN
a  ||| S:216 E:218 ||| DT
co-factor  ||| S:218 E:228 ||| JJ
in  ||| S:228 E:231 ||| IN
the  ||| S:231 E:235 ||| DT
post-translational  ||| S:235 E:254 ||| JJ
carboxylation  ||| S:254 E:268 ||| NN
of  ||| S:268 E:271 ||| IN
several  ||| S:271 E:279 ||| JJ
bone  ||| S:279 E:284 ||| NN
proteins ||| S:284 E:292 ||| NNS
.  ||| S:292 E:294 ||| .
Osteocalcin  ||| S:294 E:306 ||| NNP
( ||| S:306 E:307 ||| -LRB-
OC ||| S:307 E:309 ||| NNP
) ||| S:309 E:310 ||| -RRB-
,  ||| S:310 E:312 ||| ,
the  ||| S:312 E:316 ||| DT
most  ||| S:316 E:321 ||| RBS
abundant  ||| S:321 E:330 ||| JJ
of  ||| S:330 E:333 ||| IN
these  ||| S:333 E:339 ||| DT
bone  ||| S:339 E:344 ||| NN
matrix  ||| S:344 E:351 ||| NN
proteins ||| S:351 E:359 ||| NNS
,  ||| S:359 E:361 ||| ,
is  ||| S:361 E:364 ||| VBZ
produced  ||| S:364 E:373 ||| VBN
by  ||| S:373 E:376 ||| IN
osteoblasts  ||| S:376 E:388 ||| NN
and  ||| S:388 E:392 ||| CC
released  ||| S:392 E:401 ||| VBN
in  ||| S:401 E:404 ||| IN
small  ||| S:404 E:410 ||| JJ
amounts  ||| S:410 E:418 ||| NNS
in  ||| S:418 E:421 ||| IN
blood  ||| S:421 E:427 ||| NN
as  ||| S:427 E:430 ||| IN
a  ||| S:430 E:432 ||| DT
specific  ||| S:432 E:441 ||| JJ
marker  ||| S:441 E:448 ||| NN
of  ||| S:448 E:451 ||| IN
bone  ||| S:451 E:456 ||| NN
formation ||| S:456 E:465 ||| NN
.  ||| S:465 E:467 ||| .
Carboxylated  ||| S:467 E:480 ||| JJ
proteins  ||| S:480 E:489 ||| NNS
have  ||| S:489 E:494 ||| VBP
a  ||| S:494 E:496 ||| DT
high  ||| S:496 E:501 ||| JJ
affinity  ||| S:501 E:510 ||| NN
for  ||| S:510 E:514 ||| IN
calcium  ||| S:514 E:522 ||| NN
and  ||| S:522 E:526 ||| CC
are  ||| S:526 E:530 ||| VBP
important  ||| S:530 E:540 ||| JJ
in  ||| S:540 E:543 ||| IN
the  ||| S:543 E:547 ||| DT
incorporation  ||| S:547 E:561 ||| NN
of  ||| S:561 E:564 ||| IN
calcium  ||| S:564 E:572 ||| NN
into  ||| S:572 E:577 ||| IN
bone  ||| S:577 E:582 ||| NN
and  ||| S:582 E:586 ||| CC
bone  ||| S:586 E:591 ||| NN
formation ||| S:591 E:600 ||| NN
.  ||| S:600 E:602 ||| .
The  ||| S:602 E:606 ||| DT
increased  ||| S:606 E:616 ||| JJ
levels  ||| S:616 E:623 ||| NNS
of  ||| S:623 E:626 ||| IN
undercarboxylated  ||| S:626 E:644 ||| JJ
osteocalcin  ||| S:644 E:656 ||| NN
can  ||| S:656 E:660 ||| MD
bring  ||| S:660 E:666 ||| VB
about  ||| S:666 E:672 ||| IN
an  ||| S:672 E:675 ||| DT
alteration  ||| S:675 E:686 ||| NN
of  ||| S:686 E:689 ||| IN
the  ||| S:689 E:693 ||| DT
bone  ||| S:693 E:698 ||| NN
mineral  ||| S:698 E:706 ||| NN
density  ||| S:706 E:714 ||| NN
and  ||| S:714 E:718 ||| CC
the  ||| S:718 E:722 ||| DT
risk  ||| S:722 E:727 ||| NN
of  ||| S:727 E:730 ||| IN
fracture ||| S:730 E:738 ||| NN
,  ||| S:738 E:740 ||| ,
even  ||| S:740 E:745 ||| RB
if  ||| S:745 E:748 ||| IN
contradictory  ||| S:748 E:762 ||| JJ
results  ||| S:762 E:770 ||| NNS
have  ||| S:770 E:775 ||| VBP
been  ||| S:775 E:780 ||| VBN
observed  ||| S:780 E:789 ||| VBN
in  ||| S:789 E:792 ||| IN
several  ||| S:792 E:800 ||| JJ
epidemiologic  ||| S:800 E:814 ||| JJ
studies ||| S:814 E:821 ||| NNS
.  ||| S:821 E:823 ||| .
However ||| S:823 E:830 ||| RB
,  ||| S:830 E:832 ||| ,
some ||| S:832 E:836 ||| DT
,  ||| S:836 E:838 ||| ,
but  ||| S:838 E:842 ||| CC
not  ||| S:842 E:846 ||| RB
all  ||| S:846 E:850 ||| DT
reports ||| S:850 E:857 ||| NNS
,  ||| S:857 E:859 ||| ,
find  ||| S:859 E:864 ||| VB
that  ||| S:864 E:869 ||| DT
vitamin  ||| S:869 E:877 ||| JJ
K  ||| S:877 E:879 ||| NNP
deficiency ||| S:879 E:889 ||| NN
,  ||| S:889 E:891 ||| ,
induced  ||| S:891 E:899 ||| VBN
by  ||| S:899 E:902 ||| IN
hydroxycoumarins ||| S:902 E:918 ||| NN
,  ||| S:918 E:920 ||| ,
may  ||| S:920 E:924 ||| MD
be  ||| S:924 E:927 ||| VB
associated  ||| S:927 E:938 ||| VBN
with  ||| S:938 E:943 ||| IN
low  ||| S:943 E:947 ||| JJ
bone  ||| S:947 E:952 ||| NN
mass ||| S:952 E:956 ||| NN
.  ||| S:956 E:958 ||| .
Additionally ||| S:958 E:970 ||| RB
,  ||| S:970 E:972 ||| ,
epidemiologic  ||| S:972 E:986 ||| JJ
studies  ||| S:986 E:994 ||| NNS
have  ||| S:994 E:999 ||| VBP
found  ||| S:999 E:1005 ||| VBN
that  ||| S:1005 E:1010 ||| IN
the  ||| S:1010 E:1014 ||| DT
use  ||| S:1014 E:1018 ||| NN
of  ||| S:1018 E:1021 ||| IN
OA  ||| S:1021 E:1024 ||| NNP
may  ||| S:1024 E:1028 ||| MD
be  ||| S:1028 E:1031 ||| VB
associated  ||| S:1031 E:1042 ||| VBN
with  ||| S:1042 E:1047 ||| IN
either  ||| S:1047 E:1054 ||| DT
increased  ||| S:1054 E:1064 ||| JJ
or  ||| S:1064 E:1067 ||| CC
no  ||| S:1067 E:1070 ||| DT
change  ||| S:1070 E:1077 ||| NN
in  ||| S:1077 E:1080 ||| IN
fracture  ||| S:1080 E:1089 ||| JJ
risk ||| S:1089 E:1093 ||| NN
.  ||| S:1093 E:1095 ||| .
Such  ||| S:1095 E:1100 ||| JJ
divergent  ||| S:1100 E:1110 ||| JJ
results  ||| S:1110 E:1118 ||| NNS
may  ||| S:1118 E:1122 ||| MD
imply  ||| S:1122 E:1128 ||| VB
that  ||| S:1128 E:1133 ||| DT
human  ||| S:1133 E:1139 ||| JJ
studies  ||| S:1139 E:1147 ||| NNS
are  ||| S:1147 E:1151 ||| VBP
compromised  ||| S:1151 E:1163 ||| VBN
by  ||| S:1163 E:1166 ||| IN
the  ||| S:1166 E:1170 ||| DT
physical  ||| S:1170 E:1179 ||| JJ
illnesses  ||| S:1179 E:1189 ||| NNS
for  ||| S:1189 E:1193 ||| IN
which  ||| S:1193 E:1199 ||| WDT
OA  ||| S:1199 E:1202 ||| NNP
were  ||| S:1202 E:1207 ||| VBD
prescribed ||| S:1207 E:1217 ||| VBN
.  ||| S:1217 E:1219 ||| .
Additional  ||| S:1219 E:1230 ||| JJ
epidemiological  ||| S:1230 E:1246 ||| NN
or  ||| S:1246 E:1249 ||| CC
cohort  ||| S:1249 E:1256 ||| JJ
studies  ||| S:1256 E:1264 ||| NNS
are  ||| S:1264 E:1268 ||| VBP
warranted  ||| S:1268 E:1278 ||| VBN
in  ||| S:1278 E:1281 ||| IN
order  ||| S:1281 E:1287 ||| NN
to  ||| S:1287 E:1290 ||| TO
determine  ||| S:1290 E:1300 ||| VB
whether  ||| S:1300 E:1308 ||| IN
potential  ||| S:1308 E:1318 ||| JJ
pharmacological  ||| S:1318 E:1334 ||| JJ
effects  ||| S:1334 E:1342 ||| NNS
of  ||| S:1342 E:1345 ||| IN
VKA  ||| S:1345 E:1349 ||| NNP
on  ||| S:1349 E:1352 ||| IN
bone  ||| S:1352 E:1357 ||| NN
metabolism  ||| S:1357 E:1368 ||| NN
may  ||| S:1368 E:1372 ||| MD
have  ||| S:1372 E:1377 ||| VB
clinical  ||| S:1377 E:1386 ||| JJ
consequences ||| S:1386 E:1398 ||| NNS
.  ||| S:1398 E:1400 ||| .
